Simple, wearable, 3-day insulin delivery, so you can

Enjoy More Moments and Miss Fewer Doses
More about CeQur

CeQur is dedicated to simplifying the management of diabetes for people requiring multiple daily insulin injections.

Insulin Works

Eventually most people with type 2 diabetes (T2D) require insulin replacement therapy. Despite introduction of novel therapies, insulin remains a critical therapy for the management of diabetes. Basal and mealtime insulin is often required to achieve glucose control.

Intensifying insulin therapy is challenging

Interference of injections with daily activities, injection pain, and embarrassment make adherence difficult.

CeQur (pronunciation: “Secure” [si-kyur])

Our mission is to provide multi-day, simple, wearable delivery devices that will improve the lives of people living with diabetes by freeing them from insulin injections and enabling them to take control.

Wearable, discreet, and injection-free dosing provides

  • Less interference of injections with daily activities
  • Less injection pain
  • Less embarrassment

We are dedicated to helping people with diabetes manage their disease by developing and commercializing simple drug delivery devices that can be easily integrated into daily life.

CeQur has a platform of simple wearable 3-day devices that have been developed to provide the benefits of newer technologically advanced insulin therapies without their complexity and up-front expense. These devices have been designed to reduce the barriers and challenges of daily insulin injection therapy to enable people to achieve target glycemic control.

CeQur is headquartered in Horw, Switzerland, with operations in Cardiff, United Kingdom and Marlborough, Massachusetts.

In the News

Global Headquarters

CeQur SA
Ebenaustrasse 10
6048 Horw Luzern
Switzerland

U.S. Operations

CeQur Corporation
734 Forest Street, Suite 100
Marlborough, MA 01752
USA

Media Relations

Michele Parisi
Corporate Communications

Business Development

Jay Warner
SVP, Commercialization

Investor Relations

Douglas Gunthardt
EVP & Chief Financial Officer

 

Receive Updates by Email

You may unsubscribe at any time.